A cell surface receptor called Programmed Death-1 (PD-1) serves as a T cell checkpoint and is crucial in controlling T cell exhaustion. PDL-1 or PDL-2 engagement with PD-1 causes it to become active. When the PD-1 receptor binds to its ligands, PD-L1 and PD-L2, which are expressed on cancer cells and antigen-presenting cells, it sends inhibitory checkpoint signals to activated T cells. This suppresses T-cell effector function and allows tumor immune evasion. An appealing approach for tumor immunotherapy is to block the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway.
Activated T cells, B cells, monocytes, dendritic cells, regulatory T cells, and natural killer T cells all express PD-1. It belongs to a group of immunoglobulin domain (Ig) co-receptors that affect how the T cell receptor responds when activated by an antigen-presenting cell (APC) or an infected target cell. In contrast to PD-L2, which is only and inducibly expressed on professional APCs, PD-L1 is widely expressed and constitutively on both hematopoietic and nonhematopoietic cells, including naive T and B cells, vascular endothelial cells, and pancreatic islet cells.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V75231 | PD-1-IN-25 | 2413100-40-8 | PD-1-IN-25 (compound 43) is a potent inhibitor of PD-1/PD-L1 interaction with IC50 of 10.2 nM in HTRF assay. |
|
V75213 | PD-1/PD-L1-IN-13 | 2865841-81-0 | PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 PPI inhibitor (antagonist) with IC50 of 10.2 nM for PD-1/PD-L1 interaction. |
|
V75236 | PD-1/PD-L1-IN-17 | 2851938-36-6 | PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 PPI inhibitor (antagonist) with an IC 50 value of 26.8 nM. |
|
V75208 | PD-1/PD-L1-IN-23 | 2597056-04-5 | PD-1/PD-L1-IN-23 is a potent, orally bioactive PD-1/PD-L1 PPI inhibitor. |
|
V75230 | PD-1/PD-L1-IN-26 | 2966090-78-6 | PD-1/PD-L1-IN-26 (Compound II-14) is a potent PD-1/PD-L1 PPI inhibitor (antagonist) with IC< sub>50 at 0.0380 μM. |
|
V75247 | PD-1/PD-L1-IN-27 | 2891831-47-1 | PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 PPI inhibitor (antagonist) with IC50 of 134 nM. |
|
V75252 | PD-1/PD-L1-IN-28 | 2499965-07-8 | PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of the PD-1/PD-L1 signaling pathway (IC50=0.744 µM). |
|
V75210 | PD-1/PD-L1-IN-29 | 2665734-13-2 | PD-1/PD-L1-IN-29(S4-1) is a potent PD-1/PD-L1 PPI inhibitor (antagonist) with IC50 of 6.1 nM. |
|
V85976 | PD-1/PD-L1-IN-29 intermediate-1 | 220095-93-2 | |
|
V85968 | PD-1/PD-L1-IN-29 intermediate-2 (N-benzyloxycarbonyl-L-serine tert-butyl ester) | 59859-77-7 | |
|
V75237 | PD-1/PD-L1-IN-32 | 2765535-21-3 | PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 PPI inhibitor (IC50=2.4 nM) with anti-cancer activity. |
|
V75240 | PD-1/PD-L1-IN-33 | 2975602-78-7 | PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 PPI inhibitor. |
|
V74272 | PD-1/PD-L1-IN-34 | 2924403-17-6 | PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM) and has selective binding affinity to PD-L1 (KD =0.1554 μM). |
|
V75242 | PD-1/PD-L1-IN-36 | 2714327-65-6 | PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC50= 15 nM). |
|
V84786 | PD-1/PD-L1-IN-38 | ||
|
V83514 | PD-1/PD-L1-IN-39 | ||
|
V83414 | PD-1/PD-L1-IN-40 | ||
|
V75200 | PD-1/PD-L1-IN-9 | 2628506-54-5 | PD-1/PD-L1-IN-9 is a potent and orally bioactive PD-1/PD-L1 interaction inhibitor (antagonist) with IC50 of 3.8 nM. |
|
V37662 | NP19 | 2377916-66-8 | NP19 is a novel and potent inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction with IC50 of 12 nM in homogeneous time-resolved fluorescence (HTRF) binding assays. |
|
V75201 | PD-L1-IN-1 | 2767424-13-3 | PD-L1-IN-1 is a potent PD-L1 inhibitor (antagonist) with IC50 of 115 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
